Literature DB >> 15607836

Utility of lead-in period in cocaine dependence pharmacotherapy trials.

Adam Bisaga1, Efrat Aharonovich, Fatima Garawi, Frances R Levin, Eric Rubin, Wilfrid N Raby, Suzanne K Vosburg, Edward V Nunes.   

Abstract

We examined whether drug use behaviors during a 2-week lead-in for a pharmacotherapy trial were predictive of retention in treatment and of the level of cocaine use during the subsequent 12 weeks of treatment. Fifty cocaine dependent patients were grouped based on: (1) principal route of cocaine administration: intranasal versus smoking, and (2) level of cocaine use during the 2-week lead-in: high versus low. Results indicate that level of cocaine use during the 2-week lead-in was a significant predictor of cocaine use during the subsequent 12 weeks of treatment. Patients with reported higher level of use during the lead-in period were more likely to continue using cocaine during the treatment. Patients who used smoking as their primary route of cocaine use were more likely to drop out early in the treatment. Findings of this study suggest that route and level of cocaine use during lead-in be used as a covariate in models testing treatment effect.

Entities:  

Mesh:

Year:  2005        PMID: 15607836     DOI: 10.1016/j.drugalcdep.2004.06.007

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  16 in total

1.  A placebo-controlled trial of memantine for cocaine dependence with high-value voucher incentives during a pre-randomization lead-in period.

Authors:  Adam Bisaga; Efrat Aharonovich; Wendy Y Cheng; Frances R Levin; John J Mariani; Wilfrid N Raby; Edward V Nunes
Journal:  Drug Alcohol Depend       Date:  2010-05-26       Impact factor: 4.492

2.  Baseline cocaine demand predicts contingency management treatment outcomes for cocaine-use disorder.

Authors:  Jin H Yoon; Robert Suchting; Sarah A McKay; Guadalupe G San Miguel; Anka A Vujanovic; Angela L Stotts; Scott D Lane; Jessica N Vincent; Michael F Weaver; Austin Lin; Joy M Schmitz
Journal:  Psychol Addict Behav       Date:  2019-06-24

3.  Baseline matters: the importance of covariation for baseline severity in the analysis of clinical trials.

Authors:  Edward V Nunes; Martina Pavlicova; Mei-Chen Hu; Aimee N Campbell; Gloria Miele; Denise Hien; Donald F Klein
Journal:  Am J Drug Alcohol Abuse       Date:  2011-09       Impact factor: 3.829

4.  Design and methodological considerations of an effectiveness trial of a computer-assisted intervention: an example from the NIDA Clinical Trials Network.

Authors:  Aimee N C Campbell; Edward V Nunes; Gloria M Miele; Abigail Matthews; Daniel Polsky; Udi E Ghitza; Eva Turrigiano; Genie L Bailey; Paul VanVeldhuisen; Rita Chapdelaine; Autumn Froias; Maxine L Stitzer; Kathleen M Carroll; Theresa Winhusen; Sara Clingerman; Livangelie Perez; Erin McClure; Bruce Goldman; A Rebecca Crowell
Journal:  Contemp Clin Trials       Date:  2011-11-09       Impact factor: 2.226

5.  Effects of major depressive disorder and attention-deficit/hyperactivity disorder on the outcome of treatment for cocaine dependence.

Authors:  Frances R Levin; Adam Bisaga; Wilfrid Raby; Efrat Aharonovich; Eric Rubin; John Mariani; Daniel J Brooks; Fatima Garawi; Edward V Nunes
Journal:  J Subst Abuse Treat       Date:  2007-06-15

6.  Efficacy of an adenovirus-based anti-cocaine vaccine to reduce cocaine self-administration and reacqusition using a choice procedure in rhesus macaques.

Authors:  Suzette M Evans; Richard W Foltin; Martin J Hicks; Jonathan B Rosenberg; Bishnu P De; Kim D Janda; Stephen M Kaminsky; Ronald G Crystal
Journal:  Pharmacol Biochem Behav       Date:  2016-09-30       Impact factor: 3.533

7.  A two-phased screening paradigm for evaluating candidate medications for cocaine cessation or relapse prevention: modafinil, levodopa-carbidopa, naltrexone.

Authors:  Joy M Schmitz; Charles E Green; Angela L Stotts; Jan A Lindsay; Nuvan S Rathnayaka; John Grabowski; F Gerard Moeller
Journal:  Drug Alcohol Depend       Date:  2014-01-03       Impact factor: 4.492

8.  Multimodal predictive modeling of individual treatment outcome in cocaine dependence with combined neuroimaging and behavioral predictors.

Authors:  Sean X Luo; Diana Martinez; Kenneth M Carpenter; Mark Slifstein; Edward V Nunes
Journal:  Drug Alcohol Depend       Date:  2014-07-10       Impact factor: 4.492

9.  Placebo-group responders in methamphetamine pharmacotherapy trials: the role of immediate establishment of abstinence.

Authors:  Matthew Brensilver; Keith G Heinzerling; Aimee-Noelle Swanson; Steven J Shoptaw
Journal:  Exp Clin Psychopharmacol       Date:  2012-08-06       Impact factor: 3.157

10.  The effects of oral d-amphetamine on impulsivity in smoked and intranasal cocaine users.

Authors:  Stephanie Collins Reed; Suzette M Evans
Journal:  Drug Alcohol Depend       Date:  2016-04-19       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.